GET THE APP

..

Pharmaceutical Regulatory Affairs: Open Access

ISSN: 2167-7689

Open Access

Enzmann H

Federal Institute for Drugs and Medical Devices, Bundesinstitut für Arzneimittel und Medizinprodukte,
Kurt Georg Kiesinger Allee 3, 53175 Bonn
Germany

Publications
  • Case Report
    Development of Innovative Medicines for European Patients and Impact of Brexit
    Author(s): Enzmann H and Norta MEnzmann H and Norta M

    European patients may benefit from innovative medicines only at the end of a complex process with a sequence of positive decisions on different levels by different stakeholders. The decision of the industry to invest in a usually global clinical development must be followed by a European marketing authorization decision and a mostly national decision on price and reimbursement until finally patients and their physicians can make an individual treatment decision. Development strategies must consider the evolution of scientific and procedural requirements. Current trends are characterized by an enhanced cooperation of regulators and health technology assessment-bodies. The increasing availability of innovative personalized or precision medicines is reflected in the new procedural tools like European Medicines Agency’s priority medicines scheme and adaptive pathways concept. The UK.. Read More»
    DOI: 10.4172/2167-7689.1000171

    Abstract PDF

Relevant Topics

Google Scholar citation report
Citations: 533

Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report

Pharmaceutical Regulatory Affairs: Open Access peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward